Examkin

Soru

Zorluk: OrtaPreventive Care and Screening

A 46-year-old female presents to the primary care clinic for a routine health maintenance evaluation. She has a history of seropositive rheumatoid arthritis, which was diagnosed 4 years ago. Her disease is currently well controlled on a regimen of weekly methotrexate and subcutaneous etanercept. She feels well and reports no joint pain, stiffness, or systemic symptoms. She smoked one pack of cigarettes daily for 15 years but quit 5 years ago. She has no other chronic medical conditions, and her only other medication is a daily multivitamin. Her most recent screening tests include a normal colonoscopy at age 45 and a normal screening mammogram 8 months ago. Hepatitis B and C virus screening tests were negative 3 years ago. She received a tetanus-diphtheria-pertussis (Tdap) booster 4 years ago. She has not yet received an influenza vaccine this season. Vital signs are within normal limits, and physical examination is unremarkable. Which of the following is the most appropriate next step in preventive care for this patient?

  1. Administration of the 20-valent pneumococcal conjugate vaccineCevap
  2. B
    Administration of the live-attenuated influenza vaccine
  3. C
    Screening with low-dose computed tomography of the chest
  4. D
    Screening with a resting 12-lead electrocardiogram
  5. E
    Routine screening pelvic ultrasound

Cevap

The most appropriate next step is the administration of the 20-valent pneumococcal conjugate vaccine because the patient is immunocompromised from her rheumatoid arthritis medications.
This patient requires pneumococcal vaccination due to iatrogenic immunosuppression. According to the Advisory Committee on Immunization Practices (ACIP), adults aged 19 through 49 years who have an immunocompromising condition—such as taking immunosuppressive medications (e.g., methotrexate, TNF inhibitors like etanercept)—should receive pneumococcal vaccination. The recommended approach is a single dose of the 20-valent pneumococcal conjugate vaccine (PCV20), or alternatively, the 15-valent pneumococcal conjugate vaccine (PCV15) followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Additionally, she should receive the seasonal influenza vaccine, but it must be the inactivated formulation.

Adım Adım Çözüm

1
Analyze the patient's demographic and clinical risk profile.
The patient is a 46-year-old female on immunosuppressive therapy (methotrexate and etanercept) for rheumatoid arthritis.
Identifying iatrogenic immunosuppression is critical for determining appropriate vaccine indications and contraindications.
2
Evaluate indicated vaccinations based on the patient's risk profile.
Because of her immunosuppression, she requires pneumococcal vaccination despite being under the universal age guideline of 50 years.
ACIP guidelines recommend pneumococcal vaccination for adults aged 19-49 with an immunocompromising condition.
3
Evaluate the distractors for contraindications or lack of indication.
Live-attenuated influenza vaccine is contraindicated. She does not meet criteria for lung cancer screening, and routine ECG or pelvic ultrasound are not recommended.
Preventive care requires avoiding unnecessary testing and avoiding harm from contraindicated interventions.

Anahtar Kavram

Adults aged 19 to 49 years with an immunocompromising condition (including use of immunosuppressive medications) should receive pneumococcal vaccination (e.g., a single dose of PCV20).
Bu soruyu puanla

Konular

Preventive Care and Screening

Bu konudan daha fazla soru